Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Unfortunately for some shareholders, the Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) share price has dived 30% in the last thirty days, prolonging recent pain. For any long-term shareholders, the last month ends a year to forget by locking in a 74% share price decline.

Although its price has dipped substantially, when almost half of the companies in China's Pharmaceuticals industry have price-to-sales ratios (or "P/S") below 3.1x, you may still consider Qinghai Spring Medicinal Resources Technology as a stock not worth researching with its 5.2x P/S ratio. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified.

View our latest analysis for Qinghai Spring Medicinal Resources Technology

What Does Qinghai Spring Medicinal Resources Technology's Recent Performance Look Like?

Recent times have been quite advantageous for Qinghai Spring Medicinal Resources Technology as its revenue has been rising very briskly. Perhaps the market is expecting future revenue performance to outperform the wider market, which has seemingly got people interested in the stock. However, if this isn't the case, investors might get caught out paying too much for the stock.

We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Qinghai Spring Medicinal Resources Technology's earnings, revenue and cash flow.

How Is Qinghai Spring Medicinal Resources Technology's Revenue Growth Trending?

In order to justify its P/S ratio, Qinghai Spring Medicinal Resources Technology would need to produce outstanding growth that's well in excess of the industry.

If we review the last year of revenue growth, the company posted a terrific increase of 71%. The latest three year period has also seen an excellent 84% overall rise in revenue, aided by its short-term performance. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.

When compared to the industry's one-year growth forecast of 18%, the most recent medium-term revenue trajectory is noticeably more alluring

With this information, we can see why Qinghai Spring Medicinal Resources Technology is trading at such a high P/S compared to the industry. It seems most investors are expecting this strong growth to continue and are willing to pay more for the stock.

What We Can Learn From Qinghai Spring Medicinal Resources Technology's P/S?

A significant share price dive has done very little to deflate Qinghai Spring Medicinal Resources Technology's very lofty P/S. Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

We've established that Qinghai Spring Medicinal Resources Technology maintains its high P/S on the strength of its recent three-year growth being higher than the wider industry forecast, as expected. At this stage investors feel the potential continued revenue growth in the future is great enough to warrant an inflated P/S. If recent medium-term revenue trends continue, it's hard to see the share price falling strongly in the near future under these circumstances.

You should always think about risks. Case in point, we've spotted 2 warning signs for Qinghai Spring Medicinal Resources Technology you should be aware of, and 1 of them is concerning.

It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com